Global Organ Transplant Immunosuppressant Drugs Market
An immunosuppressant is a drug used to suppress the immune responses through a number of mechanisms. It is used in organ transplant for the purpose of preventing the body from recognizing or attacking the transplanted organ. Immunosuppressant drugs can act by preventing and treating graft-versus-host disease and can minimize destruction of affected tissues in autoimmune and inflammatory diseases. There are two types of immunosuppressant drugs, namely, induction drugs and maintenance drugs. Induction drugs are anti-rejection medicines used during the transplant, whereas, the maintenance drugs are anti-rejection medicines intended for a long-term use.
Get FREE Sample PDF Including COVID-19 Impact Analysis: https://www.coherentmarketinsights.com/insight/request-sample/2495
Global Organ Transplant Immunosuppressant Drugs Market Dynamics
Increasing number of patients with the need for organ transplants is expected to boost the global organ transplant immunosuppressant drugs market growth. According to the U.S. Government Information on Organ Donation and Transplantation, U.S. Department of Health & Human Services, in 2017, around 34770 organ transplants were performed in the U.S., and it was found that over 114000 patients were in need for organ transplant.
Moreover, increasing approvals for new products is expected to boost the global organ transplant immunosuppressant drugs market growth. For instance, in April 2017, the U.S. Food and Drug Administration (FDA) approved Thymoglobulin (anti-thymocyte globulin) produced by Sanofi. Thymoglobulin is intended to use in conjunction with concomitant immunosuppression in the prophylaxis and prevention of acute rejection in patients receiving a kidney transplant.
However, the declining number of organ transplants due to the shortage of organs may hinder the growth of the global organ transplant immunosuppressant drugs market in the upcoming years. As per the National Center for Biotechnology Information (NCBI), in 2015, only 30,973 organ transplants from 15,064 donors were performed in the U.S., while over 121,000 candidates were in need for organ transplantation. Furthermore, the Organ Donation and Transplantation Activity Report suggested that the number of organ transplants decreased from 4,655 in 2013 to 4,431 in 2015 in the U.K.
LIMITED TIME OFFER – Hurry Up!
Get Discount For Buyers UPTO 25% OFF On Any Research Report
Apply Promo Code “CHRISTMAS2020” And Get Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/2495
Global Organ Transplant Immunosuppressant Drugs Market – Regional Analysis
Increasing cases of kidney disorders in the U.S. is expected to propel growth of the organ transplant immunosuppressant drugs market in North America. According to the United Network for Organ Sharing (UNOS), in 2016, 19,061 kidney transplants were performed in the U.S. compared to 17,878 kidney transplants in 2015. Therefore, the number of kidney transplants increased by 6.6% in 2016.
Moreover, escalating number of pipeline studies to develop drugs for organ transplant rejection is expected to contribute to the growth of the regional market. For instance, in November 2018, Temple University, in collaboration with Veloxis Pharmaceuticals, initiated the phase 4 clinical trial for Tacrolimus Extended Release Oral Tablet to evaluate the dosing strategies for de novo once-daily extended release tacrolimus (LCPT) in kidney transplant recipients. The study was concluded in August 2019.
Europe is expected to witness considerable growth in the global market over the forecast timeframe. This growth is attributed to the increasing product launches by the key market players operating in this region. For instance, in 2013, Roche Group launched two new highly-sensitive therapeutic drug monitoring tests for immunosuppressant medicines – tacrolimus and cyclosporine worldwide (except U.S.). Therapeutic monitoring for immunosuppressive drugs is a major part of the transplant medicine and is crucial for maintaining the health of patients with organ transplantation for a longer period.
Key Market Players
The leading players operating in the global organ transplant immunosuppressant drugs market include Astellas Pharma, Genzyme Corporation, Accord Healthcare Ltd., Watson Pharmaceuticals, Inc., Novartis AG, Mylan Laboratories, Inc., GlaxoSmithKline Plc, Belcher Pharmaceuticals LLC, Leo Pharma As, Glenmark Pharmaceuticals Ltd., Veloxis Pharmaceuticals Inc., Dr. Reddy’s Laboratories Ltd., Panacea Biotec Ltd., Strides Pharma Global Pte Ltd., and Hoffman La Roche.
We value your investment and offer customization as per your requirements.
Share your precise requirements @ https://www.coherentmarketinsights.com/insight/request-customization/2495
By Drug Class,
- Calcineurin Inhibitors
- Antiproliferative Agents
- mTOR Inhibitor (Mammalian Target of Rapamycin)
- Immunosuppressant Antibodies
By Therapeutic Organ Transplant Type,
- Heart Transplant
- Kidney Transplant
- Liver Transplant
- Lung Transplant
- Pancreas Transplant
By Distribution Channel,
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- North America
- Asia Pacific
- Latin America
- Middle East
Have a Look at Related Research Insights:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027